Pulmonary hypertension is characterized by an increase in mean pulmonary arterial
pressure and right ventricular overload. Endothelin-1 (ET-1) is a potent vasoconstrictor with …

The endothelin system has been extensively studied over the last several years. It is clear
that endothelin-1 (ET-1) is a key mediator in pulmonary vascular biology and physiology …

Pulmonary arterial hypertension is a rapidly progressing disease characterized by an over‐
expression of endothelin. In addition to its potent pulmonary vasoconstrictor effects …

The peptide endothelin plays a significant role in a wide array of pathological conditions,
including primary pulmonary hypertension and pulmonary arterial hypertension associated …

Background—Few treatments are available for isolated pulmonary hypertension (PHT),
which has a high morbidity and mortality. This trial was designed to assess the …

Background: Endothelin-1 (ET-1) has been implicated as a key mediator in the
pathogenesis of pulmonary arterial hypertension (PAH). The potential benefits of bosentan …

Endothelin (ET) has emerged as a key mediator in the pathophysiology of pulmonary arterial
hypertension (PAH). The effects of ET are mediated by its binding to two receptors on …

Endothelin receptor antagonism has emerged as an important therapeutic approach in
pulmonary arterial hypertension (PAH). Bench to bedside scientific research has clearly …

Background Endothelin (ET)-1 has a pathogenic role in pulmonary arterial hypertension
(PAH). Recent clinical studies carried out in Western populations showed that blockade of …

Objective: The aim of this study was to investigate the efficacy of Bosentan, an endothelin
antagonist of endothelin receptors, in patients with mild to moderate pulmonary …